In adult erythroid cells, the LCR normally loops to the active adult β-globin gene, while the fetal γ-globin genes are epigenetically silenced and excluded from looping. Experiments showed that re-targeting the LCR to the γ-globin genes by using an LDB1-based artificial protein or inhibiting the H3K9 methyltransferase G9a led to relief of γ-globin silencing, redistribution of LCR looping, and increased γ-globin expression to potentially therapeutic levels for β-hemoglobinopathies. These experiments suggest that modulating chromosome looping may be a therapeutic target for gene activation in diseases like sickle cell anemia and β-thalas